SLE Archives - Page 16 of 38 - ACR Meeting Abstracts

Abstract Number: 1834 • 2017 ACR/ARHP Annual Meeting
Selective Inhibitors of Nuclear Export Prevent Lupus Progression By Targeting Germinal Center Formation and Autoreactive Antibody Secreting Cells
Javier Rangel-Moreno¹, Jennifer Barnard², Shelton Cochran³, Margaret Lee³, Sharon Tamir³ and Jennifer H. Anolik⁴, ¹Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine-Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Karyopharm Therapeutics, Newton, MA, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: There is great interest in developing new treatment approaches for systemic lupus erythematosus (SLE), but the biologic therapies under investigation over the past several…
Abstract Number: 2611 • 2017 ACR/ARHP Annual Meeting
Walk SLE – a Pilot Study Exploring Walk with Ease (WWE), a Self-Directed Walking Program, in Lupus Patients
Brittaney-Belle E. Gordon¹, Katherine Kaufman², Sean T. Hicks¹, Julie A. Norfleet¹, Rebecca J. Cleveland¹, Leigh F. Callahan³ and Saira Z. Sheikh¹, ¹Thurston Arthritis Research Center, University of North Carolina School of Medicine, Chapel Hill, NC, ²Department of Pediatrics, Duke University School of Medicine, Durham, NC, ³Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Fatigue and arthritis are common sources of impairment in SLE patients that persist despite lifestyle and pharmacologic interventions. Walk with Ease (WWE) is the…
Abstract Number: 706 • 2017 ACR/ARHP Annual Meeting
Elevated Erythrocyte Sedimentation Rate Among Obese Patients with SLE- Not Always a Marker of Disease Activity
George Stojan¹, Erik Barr² and Michelle Petri³, ¹Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, ³Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Obesity is more common in patients with SLE compared to the general population. The prevalence of obesity among SLE patients is between 28 and…
Abstract Number: 1597 • 2017 ACR/ARHP Annual Meeting
Arthritis and Hydroxychloroquine Are Associated with Decreased Risk of Macrophage Activation Syndrome Among Adults Hospitalized with SLE
Kristin D'Silva¹, Ezra Cohen², David J. Kreps³, Mary Beth Son² and Karen H. Costenbader³, ¹Internal Medicine, Brigham and Women's Hospital, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Macrophage activation syndrome (MAS) is an uncommon but potentially fatal complication of SLE. We conducted a case-control study comparing hospitalized adults with SLE with…
Abstract Number: 1835 • 2017 ACR/ARHP Annual Meeting
Microglial Defects Contribute to Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Hadijat Makinde¹, Philip J. Homan², Harris Perlman² and Carla Cuda², ¹Northwestern University, Chicago, IL, ²Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Neuropsychiatric symptoms of systemic lupus erythematosus (NP-SLE), including headaches, cognitive dysfunction and psychiatric disorders, appear in up to 75% of SLE patients and may…
Abstract Number: 2618 • 2017 ACR/ARHP Annual Meeting
Why Aren’t All Patients with SLE Taking Hydroxychloroquine? A Retrospective Chart Review
Caroline H. Siegel¹, Jennifer M. Grossman¹, John Fitzgerald¹, Bevra H. Hahn^1,2, Lori Sahakian¹, Eloise Olmos² and Maureen A. McMahon¹, ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Although previous SLE treatment guidelines recommended judicious use of antimalarials, there is a growing body of evidence demonstrating that HCQ prevents flares, protects against…
Abstract Number: 708 • 2017 ACR/ARHP Annual Meeting
Anti-RNP/Sm Antibodies Plus Lupus Anticoagulant As Risk Factor for Thrombosis in Patients with Systemic Lupus Erythematosus
Mari Carmen Zamora-Medina¹, Andrea Hinojosa-Azaola², Carlos Núñez-Álvarez³ and Juanita Romero-Diaz⁴, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutricion S.Z., Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico
Background/Purpose: In a previous study, we identify a potential role of anti-RNP/Sm in combination with LA as risk factor for thrombosis. We aimed to validate…
Abstract Number: 1611 • 2017 ACR/ARHP Annual Meeting
Increased Body Mass Index May Not be a Risk Factor for the Development of Lupus Nephritis
Yu Pei Chock¹, Abhijeet Danve¹, Wei Fu² and Michelle Petri³, ¹Rheumatology, Yale University, New Haven, CT, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Studies have indicated that increased body mass index (BMI) is a risk factor for development of Chronic Kidney Disease (CKD). Obesity is a low…
Abstract Number: 1838 • 2017 ACR/ARHP Annual Meeting
Estimating Duration of Response in Systemic Lupus Erythematosus (SLE) Trials
Mimi Kim¹, Joan T. Merrill², Kenneth C. Kalunian³, Leslie Hanrahan⁴ and Peter M. Izmirly⁵, ¹Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ⁴Lupus Foundation of America, Washington DC, DC, ⁵Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: The primary endpoint in SLE trials is usually response to therapy at a landmark visit. However, during a trial, patients may alternate between response…
Abstract Number: 2632 • 2017 ACR/ARHP Annual Meeting
The Southern California Lupus Registry: I. Baseline Characteristics of Patients with Systemic Lupus Erythematosus in an Uncharted Territory
Joshua Liu¹, Kathleen Teves², Van La², Arlene Bravo³, Sheila Lezcano⁴, Talha Khawar⁴, Ebrahim Sadeghi⁴, Cong-Bin Wang⁵, Karina Torralba⁶, Howard Yang⁵ and Vaneet K. Sandhu⁷, ¹Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA, ²Internal Medicine, University of California, Riverside, Riverside, CA, ³Internal Medicine, Loma Linda University, Loma Linda, CA, ⁴Rheumatology, Loma Linda University Medical Center, Loma Linda, CA, ⁵Loma Linda University Medical Center, Loma Linda, CA, ⁶Internal Medicine/Rheumatology, Loma Linda University, Loma Linda, CA, ⁷Division of Rheumatology, Loma Linda University, Loma Linda, CA
Background/Purpose: The Southern California Lupus Registry (SCOLR) is a population-based, longitudinal, multi-ethnic cohort of subjects with SLE directed toward studying health and healthcare disparities in…
Abstract Number: 149 • 2017 Pediatric Rheumatology Symposium
Deficiency of Complement C4A or Low Copy Number of Total C4 Genes, HLA-DRB1*15 and HLA-DRB1*03 Are Strong Genetic Risk Factors for Pediatric SLE of European Descent
Stacy Ardoin¹, Pinar Ozge Avar Aydin², Lai Hin Kimi Chan³, Katherine Lintner⁴, Yee Ling Wu^5,6, Rabheh Aziz¹, Anjali Patwardhan^7,8, Evan Mulvihill¹, Gakit Yu⁹, Bi Zhou¹⁰, Emeli Lundstrom¹¹, Leonid Padyukov¹², Kyla Driest¹³, Cagri Yildirim-Toruner¹³, Sharon Bout-Tabaku¹³, Charles Spencer¹⁴, Gloria Higgins¹, Sampath Prahalad¹⁵, Hermine Brunner¹⁶ and Chack-Yung Yu^10,17, ¹Pediatrics and Rheumatology, Nationwide Children's Hospital and The Ohio State University, Columbus, OH, ²Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁴Pediatrics, Nationwide Children's Hospital, Columbus, OH, ⁵The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, ⁶Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital, Columbus, OH, ⁷Pediatric Rheumatology, Nationwide Childrens Hospital, Columbus, OH, ⁸Pediatric Rheumatology, Nationwide Children's Hospital, Columbia, MO, ⁹Center for Molecular and Human Genetics, Nationwide Children's Hospital, Columbus, OH, ¹⁰Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, ¹¹Rheumatology, Karolinska Institute, Stockholm, Switzerland, ¹²Rheumatology Unit, Department of Medicine, Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden, ¹³Rheumatology, Nationwide Children's Hospital, Columbus, OH, ¹⁴Rheumatology, Nationwide Childrens Hospital/OSU, Columbus, OH, ¹⁵Pediatrics, Emory Children's Center, Atlanta, GA, ¹⁶Rheumatology, PRCSG, Cincinnati, OH, ¹⁷Pediatrics, Ohio State Univ, Columbus, OH
Background/Purpose: A complete genetic deficiency of complement C4 almost always leads to the pathogenesis of systemic lupus erythematosus (SLE) with childhood onset, although its prevalence…
Abstract Number: 91 • 2017 Pediatric Rheumatology Symposium
Peri-pubertal Onset of Systemic Lupus Erythematosus is Associated with Shorter than Expected Adult Height
Merav Heshin-Bekenstein¹, Aimee O. Hersh², Emily von Scheven³ and Erica Lawson¹, ¹Pediatric Rheumatology, University of California San Francisco, San Francisco, CA, ²Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ³Division of Rheumatology, Department of Pediatrics, University of California San Francisco, San Francisco, CA
Background/Purpose: Patients with childhood-onset SLE (cSLE) have a higher incidence of renal disease and may receive more intensive immunosuppression as compared to individuals with adult-onset…
Abstract Number: 13L • 2016 ACR/ARHP Annual Meeting
Low-Dose IL-2 Therapy in Refractory SLE: Results from Single Center Phase I/IIa Clinical Trial
Jens Humrich¹, Caroline von Spee-Mayer², Elise Siegert³, Angelika Rose², Martina Bertolo⁴, Philipp Enghard⁵, Falk Hiepe⁶, Tobias Alexander⁷, Eugen Feist⁸, Andreas Radbruch⁹, Gerd R. Burmester¹⁰ and Gabriela Riemekasten¹¹, ¹Department of Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ²Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ³Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ⁴Department of Rheumatology, Charité – University Medicine Berlin, Berlin, Germany, ⁵Department of Nephrology, Charité – University Medicine Berlin, Berlin, Germany, ⁶Charité – Universitätsmedizin, Berlin, Germany, ⁷Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁸Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁹Deutsches Rheumaforschungszentrum, Berlin, Germany, ¹⁰Charité – University Medicine Berlin, Berlin, Germany, ¹¹Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany

Background/Purpose: Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
Abstract Number: 771 • 2016 ACR/ARHP Annual Meeting
Preventive Effects of Glucocorticoids on Progression of Atherosclerosis in Japanese Patients with SLE
Hisaji Oshima¹, Masaki Iwasaki¹, Ikuko Tanaka², Misako Higashida³, Mari Ushikubo⁴, Eriko Takei⁵, Kumiko Akiya³ and Keisuke Izumi⁶, ¹Department of Connective Tissue Diseases, National Tokyo Medical Center, Tokyo, Japan, ²NAGOYA Rheumatology Clinic, Nagoya, Japan, ³Connective Tissue Diseases, National Tokyo Medical Center, Tokyo, Japan, ⁴Department of Connective Tissue Disease, National Tokyo Medical Center, Tokyo, Japan, ⁵Connective tissue disease, National Tokyo Medical Center, Tokyo, Japan, ⁶Connective Tissue Dseases, National Tokyo Medical Center, Tokyo, Japan
Background/Purpose: Several cross-sectional studies have shown a progression of atherosclerosis in SLE was associated with activities of SLE but not with glucocorticoid therapy. However, a…
Abstract Number: 1182 • 2016 ACR/ARHP Annual Meeting
Opiod Use and Death in Chronic Pain Patients with Systemic Lupus Erythematosis
Romy Cabacungan¹, Clifford Qualls², Wilmer Sibbitt Jr.¹, Timothy Moore¹, Luis Salayandia¹, Roderick Fields³, Suzanne Emil¹, Monthida Fangtham¹, Konstantin Konstantinov⁴, Tej Bhavsar¹ and Arthur Bankhurst⁵, ¹Rheumatology, University of New Mexico, Albuquerque, NM, ²Biostatistics, UNM, Albuquerque, NM, ³Internal Medicine/ Rheumatology, University of New Mexico School of Medicine, Albuquerque, NM, ⁴1 University Of New Mexico, University of New Mexico, Albuquerque, NM, ⁵Rheumatology, University of NM Medical Center, Albuquerque, NM
Background/Purpose: Chronic pain is one of the most common symptoms reported in patients with SLE. Treating pain in these individuals can be complex and…

Abstracts tagged "SLE"

Selective Inhibitors of Nuclear Export Prevent Lupus Progression By Targeting Germinal Center Formation and Autoreactive Antibody Secreting Cells

Walk SLE – a Pilot Study Exploring Walk with Ease (WWE), a Self-Directed Walking Program, in Lupus Patients

Elevated Erythrocyte Sedimentation Rate Among Obese Patients with SLE- Not Always a Marker of Disease Activity

Arthritis and Hydroxychloroquine Are Associated with Decreased Risk of Macrophage Activation Syndrome Among Adults Hospitalized with SLE

Microglial Defects Contribute to Neuropsychiatric Symptoms of Systemic Lupus Erythematosus

Why Aren’t All Patients with SLE Taking Hydroxychloroquine? A Retrospective Chart Review

Anti-RNP/Sm Antibodies Plus Lupus Anticoagulant As Risk Factor for Thrombosis in Patients with Systemic Lupus Erythematosus

Increased Body Mass Index May Not be a Risk Factor for the Development of Lupus Nephritis

Estimating Duration of Response in Systemic Lupus Erythematosus (SLE) Trials

The Southern California Lupus Registry: I. Baseline Characteristics of Patients with Systemic Lupus Erythematosus in an Uncharted Territory

Deficiency of Complement C4A or Low Copy Number of Total C4 Genes, HLA-DRB115 and HLA-DRB103 Are Strong Genetic Risk Factors for Pediatric SLE of European Descent

Peri-pubertal Onset of Systemic Lupus Erythematosus is Associated with Shorter than Expected Adult Height

Low-Dose IL-2 Therapy in Refractory SLE: Results from Single Center Phase I/IIa Clinical Trial

Preventive Effects of Glucocorticoids on Progression of Atherosclerosis in Japanese Patients with SLE

Opiod Use and Death in Chronic Pain Patients with Systemic Lupus Erythematosis